Phosphodiesterase 5 inhibition with sildenafil reverses exercise oscillatory breathing in chronic heart failure: A long-term cardiopulmonary exercise testing placebo-controlled study

European Journal of Heart Failure

Volumn 14, Issue 1, 2012, Pages 82-90

  Guazzi, Marco ^a   Vicenzi, Marco ^a   Arena, Ross ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Exercise oscillatory breathing; PDE5 inhibition; Pulmonary pressure

Indexed keywords

PLACEBO; SILDENAFIL;

AGED; ARTICLE; BREATHING DISORDER; BREATHING PATTERN; CARDIAC PATIENT; CARDIOPULMONARY EXERCISE TEST; CARDIOVASCULAR PERFORMANCE; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EXERCISE OSCILLATORY BREATHING; EXPLORATORY RESEARCH; FUNCTIONAL STATUS; HEADACHE; HEART FAILURE; HOT FLUSH; HUMAN; LUNG ARTERY PRESSURE; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; MALE; PILOT STUDY; PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION PRESSURE; RANDOMIZED CONTROLLED TRIAL; REVERSAL REACTION; VENOUS OXYGEN TENSION;

AGED; DOUBLE-BLIND METHOD; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; HEART FAILURE; HUMANS; HYPERTENSION, PULMONARY; LUNG; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PULMONARY CIRCULATION; PULMONARY WEDGE PRESSURE; PURINES; SULFONES; TIME; TREATMENT OUTCOME; VASCULAR RESISTANCE; VASOCONSTRICTION; VENTILATION-PERFUSION RATIO;

EID: 84555204718     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfr147     Document Type: Article

References (31)

1. Balady GJ, Arena R, Sietsema K, Myers J, Coke L, Fletcher GF, Forman D, Franklin B, Guazzi M, Gulati M, Keteyian SJ, Lavie CJ, Macko R, Mancini D, Milani RV; American Heart Association Exercise, Cardiac Rehabilitation, and Prevention Committee of the Council on Clinical Cardiology; Council on Epidemiology and Prevention; Council on Peripheral Vascular Disease; Interdisciplinary Council on Quality of Care and Outcomes Research. Clinician's Guide to cardiopulmonary exercise testing in adults: a scientific statement from the American Heart Association. Circulation 2010;122:191-225
2. Leite JJ, Mansur AJ, de Freitas HF, Chizola PR, Bocchi EA, Terra-Filho M, Neder JA, Lorenzi-Filho G. Periodic breathing during incremental exercise predicts mortality in patients with chronic heart failure evaluated for cardiac transplantation. J Am Coll Cardiol 2003;41:2175-2181. (Pubitemid 36724263)
3. Corrà U, Giordano A, Bosimini E, Mezzani A, Piepoli M, Coats AJ, Giannuzzi P. Oscillatory ventilation during exercise in patients with chronic heart failure: clinical correlates and prognostic implications. Chest 2002;121:1572-1580. (Pubitemid 34499673)
4. Corra U, Pistono M, Mezzani A, Braghiroli A, Giordano A, Lanfranchi P, Bosimini E, Gnemmi M, Giannuzzi P. Sleep and exertional periodic breathing in chronic heart failure: prognostic importance and interdependence. Circulation 2006;113:44-50. (Pubitemid 43958487)
5. Guazzi M, Arena R, Ascione A, Piepoli M, Guazzi MD. Exercise oscillatory breathing and increased ventilation to carbon dioxide production slope in heart failure: an unfavorable combination with high prognostic value. Am Heart J 2007;153: 859-867. (Pubitemid 46602158)
6. Guazzi M, Raimondo R, Vicenzi M, Arena R, Proserpio C, Sarzi Braga S, Pedretti R. Exercise oscillatory ventilation may predict sudden cardiac death in heart failure patients. J Am Coll Cardiol 2007;50:299-308. (Pubitemid 47058880)
7. Sun XG, Hansen JE, Beshai JF, Wasserman K. Oscillatory breathing and exercise gas exchange abnormalities prognosticate early mortality and morbidity in heart failure. J Am Coll Cardiol 2010;55:1814-1823.
8. Guazzi M, Boracchi P, Arena R, Myers J, Vicenzi M, Peberdy MA, Bensimhon D, Chase P, Reina G. Development of a cardiopulmonary exercise prognostic score for optimizing risk stratification in heart failure: the (P)e(R)i(O)dic (B)reathing During (E)xercise (PROBE) study. J Cardiac Fail 2010;16:799-805.
9. Guazzi M, Myers J, Peberdy MA, Bensimhon D, Chase P, Arena R. Exercise oscillatory breathing in diastolic heart failure: prevalence and prognostic insights. Eur Heart J 2008;9:2751-2759.
10. Olson TP, Franz RP, Snyder EM, O'Malley KA, Beck KC, Johnson BD. Effects of acute changes in pulmonary wedge pressure on periodic breathing at rest in heart failure patients. Am Heart J 2007;153:104.e1-e7.
11. Murphy RM, Shah RV, Pappagianopoulos PP, Hough SS, Systrom DM, Semigran MJ, Lewis GD. Exercise oscillatory ventilation is associated with abnormal exercise hemodynamics in systolic heart failure. Circulation 2010;122:A16785.
12. Ben-Dov I, Sietsema KE, Casaburi R, Wasserman K. Evidence that circulatory oscillations accompany ventilatory oscillations during exercise in patients with heart failure. Am Rev Resp Dis 1992;145:776-781.
13. Francis DP, Davies LC, Piepoli M, Rauchhaus M, Ponikowski P, Coats AJ. Origin of oscillatory kinetics of respiratory gas exchange in chronic heart failure. Circulation 1999;100:1065-1070. (Pubitemid 29416232)
14. Francis DP, Willson K, Davies LC, Coats AJ, Piepoli M. Quantitative general theory for periodic breathing in chronic heart failure and its clinical implications. Circulation 2000;102:2214-2221.
15. Guazzi M. Clinical use of phosphodiesterase-5 inhibitors in chronic heart failure. Circ Heart Fail 2008;1:272-280.
16. Alaeddini J, Uber PA, Park MH, Scott RL, Ventura HO, Mehra MR. Efficacy and safety of sildenafil in the evaluation of pulmonary hypertension in severe heart failure. Am J Cardiol 2004;94:1475-1477. (Pubitemid 39556232)
17. Lewis GD, Shah R, Shahzad K, Camuso JM, Pappagianopoulos PP, Hung J, Tawakol A, Gerszten RE, Systrom DM, Bloch KD, Semigran MJ. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation 2007;116:1555-1562. (Pubitemid 47511419)
18. Lepore JJ, Maroo A, Bigatello LM, Dec GW, Zapol WM, Bloch KD, Semigran MJ. Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide. Chest 2005;127:1647-1653. (Pubitemid 46218790)
19. Guazzi M, Tumminello G, Di Marco F, Fiorentini C, Guazzi MD. The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure. J Am Coll Cardiol 2004;44:2339-2348. (Pubitemid 39647608)
20. Behling A, Rohde LE, Colombo FC, Goldraich LA, Stein R, Clausell N. Effects of 5′-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure: a double-blind, placebo-controlled clinical trial. J Card Fail 2008;14:189-197. (Pubitemid 351444866)
21. Tedford RJ, Hemnes AR, Russell SD, Wittstein IS, Mahmud M, Zaiman AL, Mathai SC, Thiemann DR, Hassoun PM, Girgis RE, Orens JB, Shah AS, Yuh D, Conte JV, Champion HC. PDE5A inhibitor treatment of persistent pulmonary hypertension after mechanical circulatory support. Circ Heart Fail 2008;1:213-219.
22. Guazzi M, Vicenzi M, Arena R, Guazzi MD. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation 2011;124:164-174.
23. Ghophrani HA, Wiedermann R, Rose F, Shermuly RT, Olschewski H, Weissmann N, Gunther A, Walmrath D, Seeger W, Grimmiger F. Sildenafil for treatment of lung fibrosis and pulmonary hypertension; a randomized controlled trial. Lancet 2002;360:895-900. (Pubitemid 35283832)
24. Hunt SA, Abraham WT, Chin MH, eldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW; American College of Cardiology Foundation; American Heart Association. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009;119:e391-e479.
25. Guyatt GH, Nogradi S, Halcrows , Singer J, Sullivan MJ, Fallen EL. Development and testing of a new measure of health status for clinical trials in heart failure. J Gen Intern Med 1989;4:101-107. (Pubitemid 19081188)
26. Lewis GD. The role of pulmonary vasculature in heart failure with preserved ejection fraction. J Am Coll Cardiol 2009;53:1127-1129.
27. Lloyd TC Jr. Effects of increased left atrial pressure on breathing frequency in anestethized dogs. J Appl Physiol 1990;79:1973-1980.
28. Guazzi M, Samaja M, Arena R, Vicenzi M, Guazzi MD. Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol 2007;50: 2136-2144. (Pubitemid 350117342)
29. Roberts AM, Bhattacharya J, Schultz HD, Coleridge HM, Coleridge JB. Stimulation of pulmonary vagal afferent C-fibers by lung edema in dogs. Circ Res 1986;58: 512-522. (Pubitemid 16102207)
30. Ribeiro JP, Knutzen A, Rocco MB, Hartley LH, Colucci WS. Periodic breathing during exercise in severe heart failure. Reversal with milrinone or cardiac transplantation. Chest 1987;3:555-556. (Pubitemid 18006626)
31. Corrà U, Pistono M, Mezzani A, Braghiroli A, Giordano A, Lanfranchi P, Bosimini E, Gnemmi M, Giannuzzi P. Sleep and exertional periodic breathing in chronic heart failure: prognostic importance and interdependence. Circulation 2006;113:44-50. (Pubitemid 43958487)